TSAAI 2019 Annual Meeting

Chattanooga, TN US
July 19, 2019 to July 21, 2019

This activity will provide physicians and other conference attendees knowledge about new developments and updates in the field of allergy, asthma and immunology. Learners will gain expertise in how to facilitate adherence, and how to choose from among the therapies in the recently expanded armamentarium. In addition to a review of relevant guidelines and recent clinical studies, lectures will include the use of illustrative patient vignettes challenging learners to formulate and justify diagnostic and treatment strategies for patients.  Areas of discussion will include asthma, PIDD and chronic rhinosinusitis.

Commercial Support
This activity is supported by a medical education grant from CSL Behring.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Tennessee Society of Allergy, Asthma and Immunology. The American College of Allergy, Asthma, and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Practicing allergists and allied healthcare providers in the field of allergy, asthma and immunology.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Screen for common non-infectious complications of common variable immune deficiency.
  • Recognize how to treat asthma, chronic sinusitis, and eosinophilic esophagitis with biologics and how to obtain reimbursement for treatment. 
  • Describe how to manage a patient who has sensitivity to alpha-gal.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 
 
All identified conflicts of interest have been resolved.
 
     Larry Borish, MD
    Consultant/Research Grant:  Astra Zeneca
    Research Grant: GSK, NIH
    Consultant: Regeneron Sanofi/Genzyme
 
    Scott Commins, MD
    Speaker:  Genentech
    Author: Up to Date
 
    Jay Lieberman, MD
    Advisory Board Member:  DBV Technologies, Aimmune, ALK Abello
    Consultant/Advisory Board Member: Aimmune Therapeutics
    Local Site Investigator: Regeneron
 
    Phil Lieberman, MD
    Speaker:  Regeneron Sanofi
    Consultant: Astra Zeneca, Alkalos
    
    John M. Routes, MD
    Consultant: CSL Bering, Therapure Bipharma
    Independent Contractor: Takeda/Shire
 
     James Sublett, MD
    Consultant: Novartis
    Speaker: DBV, Circassia
 
    Mike Tankersley, MD
    Speaker: ALK
    Advisory Board Member: ALK
 
The following have no relevant financial relationships to disclose: 

Rohit Katial, MD
Karthik Krishnan, MD
Reba Green, Meeting Coordinator
Michelle Kittle, Meeting Coordinator
 

Course summary
Available credit: 
  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Course opens: 
07/19/2019
Course expires: 
07/21/2021
Event starts: 
07/19/2019 - 4:00pm CDT
Event ends: 
07/21/2019 - 11:30am CDT
Add to calendar: 
Rating: 
0

TSAAI 2019 Annual Meeting
The Chattanoogan Hotel, Chattanooga, TN
July 19 – 21, 2019

Agenda

Friday, July 19, 2019
4:00 – 5:00 pm        Exhibitors setup                        
6:15 – 7:00 pm        Welcome reception                        

Saturday, July 20, 2019
7:15 – 7:45 am        Registration
7:15 – 7:45 am        Breakfast & exhibits

7:45 – 8:00 am        Introduction, Karthik Krishnan, MD

8:00 – 9:00 am        IT Dosing, Mike Tankersley, MD
                                   Q & A

9:00 – 10:00 am        Alpha-Gal Update, Scott Commins, MD
                                   Q & A

10:00 – 10:30 am    Break & exhibits    

10:30 – 11:30 am    EoE Update, Jay Lieberman, MD,                 
                                  Q & A

11:30 – 12:30 pm    Chronic Sinusitis Update, Larry Borish, MD
                                  Q & A

Sunday,  July 21, 2019

7:15 – 8:00 am        Breakfast & exhibits

8:00 – 9:00 am        CVID Update on Evaluation and Treatment Options    John M Routes, MD
                                  Q & A

9:00 – 10:00 am        How to Choose the Best Biologic for My Asthma Patient    Rohit Katial, MD
                                     Q & A

10:00 – 10:30 am    Break & exhibits

10:30 – 11:30 am    Advocacy Council Update, James Sublett, MD
                                 Q & A

11:30 am        Meeting adjourn


Learning Objectives  
At the conclusion of this activity, participants should be able to:
•    Screen for common non-infectious complications of common variable immune deficiency.
•    Understand how to treat asthma, chronic sinusitis, and eosinophilic esophagitis with biologics and how to obtain reimbursement for treatment.  
•    Describe how to manage a patient who has sensitivity to alpha-gal.


Accreditation   
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Tennessee Society of Allergy, Asthma and Immunology.  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7  AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    
Target Audience
Practicing allergists, primary care physicians, and allied health care providers in the field of allergy and immunology.

Commercial Support
This activity is supported by an independent educational grant from CSL Behring.

In compliance with the Americans with Disabilities Act, TSAAI requests that any participant in need of accommodation email rgreen@pmecomm.com


 

The Chattanoogan Hotel
1201 Broad Street
Chattanooga, TN 37415
United States
+1 (855) 444-3856

Available Credit

  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Please login or create an account to take this course.